- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PRX Market Currents
more »
-
May 8 Pharmaceutical Resources (PRX): Q1 EPS of $0.80 beats by $0.08. Revenue of $272M (+17% Y/Y) beats by $42M. (PR)
Comment![Earnings, Healthcare]
PRX in Focus
more »
PRX Related Articles
more »
PRX News
more »
-
at MarketWatch.com (Feb 28, 2012)
-
at MarketWatch.com (Feb 24, 2011)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Aug 2, 2010)
PRX Press Releases and Filings
more »
-
PR Newswire (May 8, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Apr 9, 2012)
-
PR Newswire (Apr 6, 2012)
-
PR Newswire (Dec 5, 2011)
PRX Latest Transcript
more »
-
Tue, Mar 3, 2009Popular searches: Megace, par, lotrel, metoprolol, okay, prx, onconase, ondansetron, 2007, reduction.
PRX Cramer
more »
-
Tue, Feb 6, 2007
PRX Instablog posts
more »
PRX vs. ETF Alternatives
Company Description
Par Pharmaceutical Companies, Inc., incorporated in 1978 as Par Pharmaceutical, Inc., is a Delaware holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing and distributing generic and... More
